Publikationen in Zusammenarbeit mit Forschern von National Cancer Institute (10)

2017

  1. Therapeutic effects of XPO1 inhibition in thymic epithelial tumors

    Cancer Research, Vol. 77, Núm. 20, pp. 5614-5627

2015

  1. Molecular pathways: Anticancer activity by inhibition of nucleocytoplasmic shuttling

    Clinical Cancer Research, Vol. 21, Núm. 20, pp. 4508-4513

2009

  1. Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients

    British Journal of Cancer, Vol. 100, Núm. 1, pp. 145-152

2008

  1. Apoptosis pathways and new anticancer agents

    Principles of Molecular Oncology: Third Edition (Humana Press), pp. 257-268

  2. Genotype analysis of the VNTR polymorphism in the SMYD3 histone methyltransferase gene: Lack of correlation with the level of histone H3 methylation in NSCLC tissues or with the risk of NSCLC

    International Journal of Cancer

  3. Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target

    PLoS ONE, Vol. 3, Núm. 3

  4. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells

    Molecular Pharmacology, Vol. 73, Núm. 4, pp. 1290-1300

  5. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors

    Annals of Oncology, Vol. 19, Núm. 9, pp. 1605-1612

2007

  1. Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain

    Molecular Cancer, Vol. 6

2004

  1. Diabetes and exocrine pancreatic insufficiency in E2F1/E2F2 double-mutant mice

    Journal of Clinical Investigation, Vol. 113, Núm. 10, pp. 1398-1407